JP6502853B2 - ムチンが関与する疾患の処置 - Google Patents

ムチンが関与する疾患の処置 Download PDF

Info

Publication number
JP6502853B2
JP6502853B2 JP2015546778A JP2015546778A JP6502853B2 JP 6502853 B2 JP6502853 B2 JP 6502853B2 JP 2015546778 A JP2015546778 A JP 2015546778A JP 2015546778 A JP2015546778 A JP 2015546778A JP 6502853 B2 JP6502853 B2 JP 6502853B2
Authority
JP
Japan
Prior art keywords
cancer
composition
composition according
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015546778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502981A (ja
JP2016502981A5 (enExample
Inventor
デイビッド エル． モリス
デイビッド エル． モリス
アストン　ロジャー
ロジャー アストン
ジェイブド アクター
ジェイブド アクター
クリシュナ ピライ
クリシュナ ピライ
Original Assignee
ニューサウス イノベイションズ ピーティーワイ リミテッド
ニューサウス イノベイションズ ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012905519A external-priority patent/AU2012905519A0/en
Application filed by ニューサウス イノベイションズ ピーティーワイ リミテッド, ニューサウス イノベイションズ ピーティーワイ リミテッド filed Critical ニューサウス イノベイションズ ピーティーワイ リミテッド
Publication of JP2016502981A publication Critical patent/JP2016502981A/ja
Publication of JP2016502981A5 publication Critical patent/JP2016502981A5/ja
Application granted granted Critical
Publication of JP6502853B2 publication Critical patent/JP6502853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22032—Stem bromelain (3.4.22.32)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
JP2015546778A 2012-12-17 2013-12-17 ムチンが関与する疾患の処置 Active JP6502853B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012905519 2012-12-17
AU2012905519A AU2012905519A0 (en) 2012-12-17 Treatment of diseases involving mucin
PCT/AU2013/001474 WO2014094041A1 (en) 2012-12-17 2013-12-17 Treatment of diseases involving mucin

Publications (3)

Publication Number Publication Date
JP2016502981A JP2016502981A (ja) 2016-02-01
JP2016502981A5 JP2016502981A5 (enExample) 2017-01-19
JP6502853B2 true JP6502853B2 (ja) 2019-04-17

Family

ID=50977393

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015546778A Active JP6502853B2 (ja) 2012-12-17 2013-12-17 ムチンが関与する疾患の処置

Country Status (13)

Country Link
US (2) US11369666B2 (enExample)
EP (1) EP2931296B1 (enExample)
JP (1) JP6502853B2 (enExample)
KR (1) KR102255753B1 (enExample)
CN (2) CN104968358B (enExample)
AU (3) AU2013362878B2 (enExample)
CA (1) CA2895149C (enExample)
DK (1) DK2931296T3 (enExample)
ES (1) ES2727686T3 (enExample)
NZ (1) NZ631536A (enExample)
TR (1) TR201907858T4 (enExample)
WO (1) WO2014094041A1 (enExample)
ZA (1) ZA201503979B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071118B2 (en) 2015-07-16 2018-09-11 Prospect Charactercare Rwmc, Llc Compositions and methods for treating peritoneal cancers
AU2016340017B2 (en) * 2015-10-14 2023-10-05 Newsouth Innovations Pty Limited Compositions and methods for the treatment of diseases involving mucin
JPWO2017195792A1 (ja) * 2016-05-13 2019-03-14 国立大学法人 熊本大学 新規なｐｅｇ修飾酵素及びそれを用いた抗がん剤デリバリー
CN108066413A (zh) * 2016-11-15 2018-05-25 李雁 标准桃金娘油的癌性黏液溶解作用及抗肿瘤新用途
AU2019225453B2 (en) * 2018-02-23 2025-03-13 MUCPharm Pty Ltd Formulations containing mucin-affecting proteases
ES2988904T3 (es) 2019-03-07 2024-11-22 Nobo Medicine Inc Inhibidores de caspasa y métodos de utilización de los mismos
WO2021217221A1 (en) * 2020-05-01 2021-11-04 MUCPharm Pty Ltd Preventing and treating viral infections
EP4422673A4 (en) * 2021-10-27 2025-07-30 MUCPharm Pty Ltd METHODS FOR THE TREATMENT OF RESPIRATORY DISEASES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
DE4302060A1 (de) * 1993-01-26 1994-07-28 Mucos Pharma Gmbh & Co Verwendung von Bromelain zur Krebstherapie und/oder Metastasen-Prophylaxe
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH08337532A (ja) 1995-06-14 1996-12-24 Takeda Chem Ind Ltd 医薬組成物
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CH695414A5 (de) * 2001-05-30 2006-05-15 Guenter Holzner Kosmetische Präparate gegen die Alterung der menschlichen Haut in einer Mehrkammer-Mischpackung.
US6517832B1 (en) * 2001-08-24 2003-02-11 Jeffrey L. Marrongelle Formulations and methods for treating chronic migraine
ATE418271T1 (de) * 2003-11-26 2009-01-15 Hills Pet Nutrition Inc Verfahren zur verringerung des exkrementgeruchs von heimtieren
US20070166362A1 (en) * 2004-10-07 2007-07-19 Shuji Sakuma Transdermal and transmucosal preparations
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20080075710A1 (en) * 2006-09-25 2008-03-27 Liquid Potions Llc Herbal composition for treating hangovers
US20100166726A1 (en) * 2007-03-07 2010-07-01 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
TWI461193B (zh) * 2009-07-24 2014-11-21 Taipei Veterans General Hospital 水飛薊或水飛薊賓用於治療神經受損之用途
JP5614978B2 (ja) * 2009-12-22 2014-10-29 独立行政法人農業・食品産業技術総合研究機構 穀物由来のプロアントシアニジン含有抽出物、及びその製造方法
CN103285383B (zh) * 2013-06-03 2015-01-07 海南通用同盟药业有限公司 一种包含菠萝蛋白酶的药物组合物及菠萝蛋白酶肠溶片

Also Published As

Publication number Publication date
US20150343035A1 (en) 2015-12-03
EP2931296A4 (en) 2016-08-10
AU2019203315A1 (en) 2019-05-30
CN116077631A (zh) 2023-05-09
AU2013362878B2 (en) 2017-03-30
WO2014094041A1 (en) 2014-06-26
DK2931296T3 (da) 2019-06-03
CN104968358A (zh) 2015-10-07
US20220401529A1 (en) 2022-12-22
JP2016502981A (ja) 2016-02-01
CA2895149A1 (en) 2014-06-26
KR20150096445A (ko) 2015-08-24
TR201907858T4 (tr) 2019-06-21
AU2017204436B2 (en) 2019-05-30
EP2931296A1 (en) 2015-10-21
NZ631536A (en) 2016-12-23
US11369666B2 (en) 2022-06-28
AU2013362878A1 (en) 2015-06-18
HK1211213A1 (en) 2016-05-20
AU2017204436A1 (en) 2017-07-20
ZA201503979B (en) 2017-11-29
CA2895149C (en) 2023-08-22
ES2727686T3 (es) 2019-10-17
EP2931296B1 (en) 2019-02-27
CN104968358B (zh) 2022-11-18
KR102255753B1 (ko) 2021-05-26

Similar Documents

Publication Publication Date Title
JP6502853B2 (ja) ムチンが関与する疾患の処置
JP4779971B2 (ja) ヒストンデアセチラーゼ阻害剤とトポイソメラーゼｉｉ阻害剤とからなる抗腫瘍剤
JP6666494B2 (ja) がんの処置のための医薬の組合せ
JP2015512398A (ja) Ｐｆｋｆｂ２阻害剤および抗癌治療法としての使用方法
JP2005538093A (ja) 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
JP6483736B2 (ja) 癌の治療のためのキナーゼ阻害剤
US11364286B2 (en) Compositions and methods for the treatment of diseases involving mucin
CN121218988A (zh) 治疗未接受bcl2抑制剂的受试者的癌症的方法
CN102440987B (zh) 含有芹菜素及芹菜素类衍生物和青蒿素及青蒿素类衍生物的药物组合物及其应用
HK1211213B (en) Treatment of diseases involving mucin
US20190015362A1 (en) Bezafibrate for the treatment of cancer
KR20140105231A (ko) 펜톡시필린을 포함하는 항암치료 보조제
JP2009107928A (ja) パウ・フェロから単離された新規化合物
HK1222548B (en) Pharmaceutical combinations for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161201

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20161226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190322

R150 Certificate of patent or registration of utility model

Ref document number: 6502853

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250